Preferred Label : duvelisib;

CISMeF synonym : IPI-145;

UNII : 610V23S0JI;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3315467/fr/copiktra-duvelisib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
duvelisib
administration, oral
Recurrent Chronic Lymphocytic Leukemia
leukemia, lymphocytic, chronic, B-Cell
Refractory Chronic Lymphocytic Leukemia
lymphoma, follicular
Refractory Follicular Lymphoma
evaluation of the transparency committee
Copiktra
duvelisib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
duvelisib
duvelisib
drug approval
europe
duvelisib
antineoplastic agents
antineoplastic agents
lymphoma, follicular
leukemia, lymphocytic, chronic, B-Cell
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Refractory Follicular Lymphoma
administration, oral
drug monitoring
phosphatidylinositol 3-Kinase
adult
aged
drug interactions
pregnancy
breast feeding
PIK3CG protein, human
Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform
Copiktra
isoquinolines
purines
isoquinolines
purines
class ib phosphatidylinositol 3-Kinase
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.